Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphomaMax S. Topp, Izidore S. Lossos, Axel Florschütz et al.|Journal of Cancer Research and Clinical Oncology|2022Cited by 10